CLN Stock Overview
An integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Celon Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł26.40 |
| 52 Week High | zł32.90 |
| 52 Week Low | zł14.00 |
| Beta | 0.71 |
| 11 Month Change | -18.27% |
| 3 Month Change | -7.04% |
| 1 Year Change | 78.86% |
| 33 Year Change | -17.88% |
| 5 Year Change | -41.14% |
| Change since IPO | 18.49% |
Recent News & Updates
Recent updates
A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price
Aug 21
Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates
Sep 24Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans
Jul 13We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow
Nov 04We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth
Aug 04Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly
May 23Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)
Mar 02Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
Feb 09
Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?
Jan 20Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain
Dec 24Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet
Dec 03Shareholder Returns
| CLN | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | 1.9% | -3.7% | -3.6% |
| 1Y | 78.9% | 42.9% | -0.01% |
Return vs Industry: CLN exceeded the Polish Pharmaceuticals industry which returned 42.9% over the past year.
Return vs Market: CLN exceeded the Polish Market which returned -0% over the past year.
Price Volatility
| CLN volatility | |
|---|---|
| CLN Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in PL Market | 8.6% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: CLN's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: CLN's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 566 | Maciej Wieczorek | www.celonpharma.com |
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland.
Celon Pharma S.A. Fundamentals Summary
| CLN fundamental statistics | |
|---|---|
| Market cap | zł1.42b |
| Earnings (TTM) | -zł45.48m |
| Revenue (TTM) | zł206.81m |
6.9x
P/S Ratio-31.3x
P/E RatioIs CLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLN income statement (TTM) | |
|---|---|
| Revenue | zł206.81m |
| Cost of Revenue | zł62.64m |
| Gross Profit | zł144.16m |
| Other Expenses | zł189.65m |
| Earnings | -zł45.48m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 20, 2024
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 69.71% |
| Net Profit Margin | -21.99% |
| Debt/Equity Ratio | 0% |
How did CLN perform over the long term?
See historical performance and comparison